Today, BioNTech $BNTX reported quarterly results, which currently focuses on, for example, the development and research of drugs aimed at treating cancer and infectious diseases. Q2 2023 earnings were in the red, with the company reporting a loss of -190.4 million, compared to a profit of 1.7 billion in Q2 2022. The company has invested heavily in R&D this year, so hopefully it will do well :)

Revenue for Q2 2023 was €167.7 million, down from €3.2 billion in Q2 2022, and also missing the estimate of €607.8 million.


As has been written here, the drop in sales is really big, but it's probably really just because of the covid.

Wow, that's a pretty massive drop in sales...

I also think they shot up the covid a lot but now it's dead again...

Crazy, is there also a hit of a drop in sales from covid products or is the problem elsewhere?

Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Posts StockBot Tracker